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Abstract
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the West and is an
incurable malignancy. No firmly established evidence exists for environmental risk-factors in the
etiology of CLL. However, CLL is estimated to have one of the highest familial risks for a
hematologic malignancy; this along with other evidence strongly supports an inherited genetic
component. In the past five years, genome-wide association studies have provided the foundation
for new avenues in the investigation of pathogenesis of this disease with 22 susceptibility loci
currently identified. We review here the advances made in identifying these loci, the potential to
translate these findings into clinical practice, and future directions needed to advance our
understanding of the genetic susceptibility of CLL.
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Introduction
Chronic lymphocytic leukemia (CLL) is a neoplasm of the blood and is one of the most
common B-cell malignancies in individuals of European ancestry in the United States; in
2013, ~16,000 individuals are expected to be diagnosed1. It is clinically defined by the
presence of a clonal population of B-cell lymphocytes of more than 5 ×109 cells/L that have
a characteristic immunophenotype2. CLL is considered a subtype of non-Hodgkin
lymphoma (NHL), and because CLL and small lymphocytic leukemia (SLL) have the same
immunophenotype and similar clinical course, CLL and SLL are typically combined
together, despite the more prominent nodal involvement in SLL. CLL is an adult cancer with
© 2013 Elsevier Inc. All rights reserved.
*Corresponding Author: Susan L. Slager, PhD, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st
Street SW, Rochester, MN 55905. Telephone: 507-284-5965; Fax: 507-284-9542; slager@mayo.edu.
Disclosure of Potential Conflicts of Interest: The authors declare that they have no conflicts of interest or competing financial or
personal relationships that could inappropriately influence the content of this article.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Semin Hematol. Author manuscript; available in PMC 2014 October 01.
Published in final edited form as:













a median age at CLL diagnosis ranging between 65–72 years3–6. Between 1975 and 2009,
the incidence of CLL was 4.2 per 100,000, increases with age, and was nearly twice as high
in males as females6. Although there has been a dramatic evolution in the treatment options
for the clinical care of CLL patients over the past decade, it still remains an incurable
malignancy. It is hoped that expanding our understanding of the pathogenesis of CLL can
both suggest translational targets and delay/prevent progression of the precursor to CLL. No
environmental risk factor has been consistently and reproducibly identified to be associated
with CLL risk7. However, CLL has one of the highest familial risks of any cancer,
suggesting a strong inherited genetic component8. In this review, we present the published
studies which demonstrate the strong familial risk of CLL as well as the studies which have
identified the currently known 22 CLL susceptibility loci. Furthermore, we discuss both the
potential impact these findings could have on clinical practice as well as future directions for
research into the genetics of CLL.
Familial risk of CLL
Diverse lines of evidence support a strong inherited genetic component of CLL risk. Initial
case-control studies reported a significant association of family history with
lymphoproliferative (LP) tumors9,10. More recently, the InterLymph consortium pooled data
from 10,211 non-Hodgkin lymphoma (NHL) cases and 11,904 controls to evaluate risk of
LP. They found a significant risk of CLL for those with a family history of any LP (1.8 fold
increase) or family history of any leukemia (2.2 fold increase risk). In Norway, investigators
used a combination of questionnaire data and registry data to examine familial occurrence of
CLL. They reported that 18% of CLL patients had a family history of hematologic disease
and relatives of patients had a 6-fold risk of developing CLL11. Finally, Goldin et al. have
published a series of population-based studies linking cancer registry with population-based
registries from Sweden12,13. In these analyses, the risk of CLL was evaluated in 26,947 first-
degree relatives of 9,717 CLL patients compared to that of 107,223 first-degree relatives of
38,159 matched controls. Relatives of CLL patients had an 8.5 fold increase risk of CLL and
a 1.9 fold increase risk of NHL.
Monoclonal B-cell Lymphocytosis (MBL) and CLL families
MBL is an asymptomatic hematologic condition characterized by a small number of B-cell
clones with a surface phenotype similar to that of CLL14,15. These clones are detectable at
low cell numbers in otherwise healthy individuals using sensitive 6 or 8 color flow
cytometry analysis. The condition was recognized when this technology revealed clonal B-
cell expansions in adults, particularly, in a series of environmental health studies14 and in
studies of asymptomatic members of CLL kindred16. MBL can be stratified by the absolute
B-cell count into “low count” (normal ALC) and “clinical” (lymphocytosis present) MBL.
Individuals with low count MBL have a very low risk of progression. However, for those
with lymphocytosis, the risk of progression to CLL is approximately 1–2% per year17. The
majority of patients identified from the general population have low count MBL. We and
others have reported MBL in 13–18% of first-degree relatives of CLL patients in high-risk
families (i.e., families with 2 or more members with CLL)16,18. This can be compared to 3–
5% in the general population using comparable laboratory detection methods and suggests
that MBL is a marker of inherited predisposition to CLL19–21. Goldin et al. recently reported
results of multi-parameter flow cytometry in 505 first-degree relatives with no personal
history of lymphoproliferative disease from 140 families having at least two cases of CLL22.
Consistent with earlier data, 17% of relatives had MBL. Age was the most important
determinant in which the probability for developing MBL by age 90 is estimated to be as
high as 61%. MBL clustered in certain families; however, clustering was independent of the
number of known CLL cases in a family with two or more CLL members. As is the case
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with CLL, males had a significantly higher risk for MBL (19.5%) than did females (15.2%,
p=0.04). The high rate of MBL and male predominance in high-risk CLL families implies a
shared inherited risk with CLL. Most of the MBL cases in high-risk CLL families have low-
count MBL. Further immunophenotypic, cytogenetic, and gene expression studies of MBL
clones from these families show heterogeneity of the clones although the majority has
features of good prognosis of CLL, such as a high prevalence of 13q deletions23. If MBL is
an early step in the process of development of CLL, then germline genes are likely to be
acting early in leukemogenesis with more oncogenic events required before CLL develops.
Linkage Studies of CLL
Partly based on the strong evidence for a high familial contribution to CLL, investigators
have performed family-based linkage studies of kindred that have two or more related
individuals with CLL. These studies represent unbiased genome screens, which can assess
the correlation between germline genetic markers and the inheritance of CLL. They are
unbiased with regard to the fact that prior biological knowledge is not required for genomic
localization. In addition, they are amenable to identifying moderately and rare variants that
have large effect sizes24. To date, three linkage studies have been performed25–27. The two
earlier linkage studies25,26 identified interesting regions but none achieved statistical
significance. The more recent study27 and the largest of the three included 206 CLL families
with 7,495 genotyped SNPs. Significant linkage was identified on chromosomal band
2q21.2. Other regions of interest from this study were identified on chromosomal bands
5q23.2, 6p22.1, 11q12.1, and 18q21.1. The 2q21.2 region contains the chemokine receptor
(CXCR4) gene, which plays a key role in B lymphopoiesis, and the region on 6q22.1
corresponds to the major histocompatibility locus. Several factors now favor population
studies over additional follow-up linkage studies in CLL families to further evaluate and
validate these findings. These include the rarity of CLL, difficulty in collecting CLL
families, as well as the theoretical findings by Risch and Merikangas28 that studies of
unrelated individuals with over a million variants genotyped could be more powerful than
studies of related individuals with only 10,000 variants genotyped. However, in a follow-up
sequencing study of the top linkage signal, the coding and splice site regions within CXCR4
were sequenced in 188 familial CLL patients and 213 controls29. There was no evidence of
modestly frequent variants with large effect size, but instead rare functional coding variants
with frequencies of 0.5% in the cases but not in the controls. These findings suggest rare
variants can contribute to CLL risk.
Candidate gene studies
Candidate gene studies are hypothesis driven studies based on partial or associative
relationships between genes and possible involvement in a related pathway underlying a
disease, such as CLL. Prior to 2007, a large number of candidate gene studies were
performed in CLL (reviewed elsewhere30), but with little durable success. Most often, they
were typically underpowered, included no independent validation, were too liberal in
statistical significance, and had the fundamental limitation that they failed to include
heretofore unknown genes. Further, given the available technology at the time, the
evaluation of the selected genes was not comprehensive but rather based on a small number
of putative functional variants from each gene. As a result, most of the initial findings had
not been replicated in larger and better powered studies. A more recent larger candidate gene
study was performed in which 692 CLL cases and 748 controls of European descent from
Spain had 613 single nucleotide polymorphisms (SNPs) successfully genotyped from 172
genes involved in cancer biology (e.g., DNA repair, apoptosis)31. Significant findings
(P<10−5) were observed for 4 SNPs in CCNH, APAF1, IL16, and CASP8, two of which
APAF1 and CASP8 are both involved in apoptosis. Interestingly, SNPs from CASP8 and
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CCNH were also evaluated in an earlier study with 992 CLL cases and 2,707 controls of
European descent from the United Kingdom, but were found not to be statistically
significant in the prior study32. The discrepancy suggests possible CLL heterogeneity across
the two studies or either set of results are due to chance. This latter point underscores the
need for improved gene coverage, larger samples sizes, and consortial participation
characteristic of more recent studies that are systematically resulting in a more accurate list
of susceptibility genes.
Genome-wide Association Studies (GWAS)
With the results of the HapMap project and the development of massively parallel array-
based genotyping technologies, genome-wide association studies (GWAS) became feasible
in 2007 nearly 10 years from the original hypothesis of Risch and Merikangas28. Similar to
linkage studies, these are unbiased genome screens to identify common risk variants with
modest effect sizes. The practice of GWAS has resulted in strong rigorous criteria for
stringent statistical significance and incorporation of validation samples to declare a novel
susceptibility locus. As a result, GWAS discovered loci have demonstrated more consistent
replication in independent studies. The first GWAS of CLL was performed in 2008 and
included 505 CLL cases and 1,438 controls with European ancestry from the United
Kingdom who had 299,983 SNPs passing genotyping quality control33. Six loci were
identified and validated on chromosomal bands 2q13, 2q37.1, 6p25, 11q24, 15q23, and
19q13. Additional independent studies validated 5 of the 6 loci with the 19q13 locus having
inconsistent findings34,35 A follow-up analysis of the initial GWAS identified 5 additional
susceptibility loci on 2q37.3, 8q24.21, 15q25.2, 15q21.3, and 16q24.1 for a total of 11 novel
CLL susceptibility loci36,37. The second GWAS of CLL was conducted in a study of
individuals of European ancestry from the San Francisco Bay area and included 148 CLL
cases and 592 controls which had 339,528 SNPs successfully genotyped38. While no novel
CLL loci were identified in this GWAS, the 6p23 and 11q24 regions identified by the first
GWAS were validated. The third GWAS of CLL, led by Slager et al., included 407 CLL
cases of which 102 were familial CLL cases, and 296 controls, all of whom were of
European descent and had 827,777 successfully genotyped SNPs39. Independent variants
located in the IRF8 gene were identified and validated within the 16q24.1 locus. Further,
this third GWAS study performed a subset analysis of familial CLL cases versus controls
and identified and validated a novel susceptibility locus within the 6p21.3 region, which
includes the major histocompatibility locus; this locus had been also identified in a prior
linkage study27. These results possibly suggest a stronger effect of the genetic variants in
familial CLL cases compared to that in sporadic CLL cases.
For CLL (and may other diseases), the number of discovered GWAS loci increases with
larger sample sizes40. The initial three CLL GWASs included between 148 and 505 CLL
cases. A meta-analysis that combined the data from these three studies for a total of 1,121
CLL cases and 3,745 controls of European descent identified and validated one additional
novel region on 6p21.31 that achieved genome-wide significance41. This finding was
subsequently replicated in an independent sample of 1,196 CLL cases and 1,699 controls42.
By far the largest GWAS of CLL to date, was recently undertaken that included a 3-stage
study of 3,100 CLL cases and 7,667 controls43 from 26 international studies. From this
endeavor, ten independent SNPs for CLL risk in nine novel loci were discovered on
chromosomal bands 10q23.31, 18q21.33, 11p15.5, 4q25, 2q33.1, 9p21.3, 18q21.32,
15q15.1, and 2p22.2, as well as one independent SNP at an established locus on 2q13. A
number of these novel loci are located in or near genes involved in apoptosis. Of the prior 13
GWAS discovered loci, all were replicated except one on chromosomal band 15q25.2 in the
stage 1 of the study, which had 2,179 CLL cases and 6,221 controls genotyped; it was
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marginally significant in the meta-analysis (P= 0.03). This could be a real finding with
modest effect size that exhibits heterogeneity. Further studies are needed to elucidate this
finding. Including the 15q25.2 locus, we now have a total of 25 independent SNPs from 22
novel loci (Table 1). Interesting, only one of the prior candidate gene study findings of
CASP8 replicated in the GWAS study. Taken together, these 25 GWAS-discovered variants
can explain approximately ~17% of the genetic heritability of incident CLL.
Post-GWAS studies
The CLL GWAS discovered SNPs do not directly account for the underlying biological
effect of the susceptibility allele, but instead surrogates for one or more underlying
susceptibility haplotypes. Interestingly, many of the GWAS SNPs are located in intergenic
regions. A more comprehensive evaluation of the regions and better understanding of
regulatory mechanisms is needed to identify potentially functional genetic variants for
laboratory evaluation. Strategies to unravel the underlying biology of these regions include
fine-mapping studies, expression quantitative loci (eQTL) studies, and multi-ethnic studies,
as well as studies assessing GWAS discovered variants in MBL, the precursor to CLL.
Fine-mapping studies survey the often large number of variants genotyped within a small
genomic region of interest in order to evaluate the linkage disequilibrium pattern,
particularly between the GWAS marker SNPs and highly correlated surrogates that could be
functionally important. Two fine-mapping studies of CLL GWAS discovered regions have
been published so far: one for the IRF4 gene located on chromosome 6p25.344 and one for
the IRF8 gene located on chromosome 16q24.145. In both of these studies, the GWAS
discovered variant was located within non-coding regions of the genes (the 3′-untranslated
region [3′UTR] of IRF4 and intron 3 of IRF8, respectively). Comprehensive sequencing of
each region was performed, and subsequent work identified additional variants associated
with CLL risk in the 3′ untranslated region (3′UTR) of each gene, which are generally not
translated and alter gene expression. Future biological studies can now use the ENCODE46
data set along with other data to generate detailed hypotheses for further laboratory studies
needed to understand the underlying biological effects of one or more susceptibility alleles.
To determine if CLL GWAS discovered variants alter gene expression, expression
quantitative trait linkage (eQTL) analysis has emerged as useful tool, especially in
CLL33,39,44,45,47. A number of promising correlations have been identified. However, all of
these studies used publically available data from unselected samples. Future studies
correlating gene expression profiles in CLL cells with germline variant data are needed to
determine the specificity of the findings. Epigenetic studies may also help to identify the
molecular basis of susceptibility variants that are located outside of the gene coding regions.
Multi-ethnic studies provide insight into sharing of alleles across populations. Although the
incidence of CLL varies substantially across ethnicities, with the highest rates in European
populations and the lowest rates in Asians, the clinical and pathological features of CLL
have been shown to be similar48,49. Two studies have assessed GWAS discovered SNPs in
Chinese48 and African American50 ethnicities. In the Chinese study, 71 CLL cases and
1,273 controls had 6 GWAS SNPs genotyped; of which 3 resulted in significant associations
with CLL risk (rs872071, rs13397985, rs17483466). In the African American study, 110
CLL African American cases were genotyped for 15 GWAS discovered SNPs. The CLL
allele frequencies from these SNPs were then compared to those publically available African
American control samples (HapMap and published African American GWAS of prostate
cancer). None of the SNPs showed significant associations (P> 0.05) with CLL risk in
African Americans. It is well-known that allele frequencies vary across ethnicities, and this
is exemplified in the findings from these two studies. Table 2 lists 4 CLL GWAS SNPs in
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which allele frequencies are available across the different ethnic control groups. In all cases,
the allele frequencies of the risk alleles in the non-European studies are lower than that in
the European studies. Interestingly, migration studies have shown that Asian subjects, e.g.,
retain the lower CLL rates characteristic of their country of origin when they migrate to the
West51–53. This is consistent with a genetic contribution to CLL etiology and lower
frequencies of risk alleles observed in Asians would be consistent with the lower CLL rates,
although larger studies are needed to verify these early observations. Moreover, new CLL
GWAS are needed in different populations to identify novel loci specific to those ethnic
groups surveyed as well as identify SNPs that are common susceptibility loci across
populations.
Two studies have evaluated the variants discovered in CLL GWAS in studies designed to
evaluate MBL39,54, the precursor condition to CLL. The larger study54 had assessed 10
GWAS variants in a meta-analysis of 419 MBL cases and 1,753 controls obtained from
three studies. Significant associations (P<0.05) were observed in 6 of the 10 evaluated
variants. Three of the non-significant variants had elevated effects suggesting possible
statistical power issue due to small sample size. Only the rs11083846 on 19q13.3 had little
evidence of an association. These results from these 9 of 10 SNPs further support that MBL
is a precursor to CLL. However, because not all individuals with MBL progress to CLL,
further studies are needed to determine perhaps additional genetic and non-genetic factors
associated with progression to CLL.
Clinical direction
The clinical utility of GWAS-discovered variants has yet to be determined in rigorous
studies. As described earlier, first-degree relatives of CLL patients have an 8.5- fold relative
risk for developing CLL and are also at increased risk for developing other indolent forms of
NHL compared to relatives of matched controls13. With the exception of the variants in the
major histocompatibility locus on 6p21.3, the GWAS discovered variants have been
identified in an unselected sample of CLL cases (i.e., regardless of family history of CLL).
Risk-prediction models that incorporate the GWAS variants along with ethnicity, family
history, and sex may identify those with greater risk. Studies are planned or underway to
determine if the now 25 GWAS-discovered SNPs stratify CLL cases based on clinical
outcome. Exome sequencing studies to identify the somatic mutations in CLL tumor cells
will complement these efforts55. Finally, with the detection of a catalog of germline
susceptibility alleles for CLL risk, there is an opportunity to assess whether these variants
are also pointing towards possible drug targets for prevention or therapeutic studies.
Summary and Future Directions
The 22 GWAS-discovered loci provide new leads to focus our efforts in understanding
genetic susceptibility of CLL. These new findings focus our attention on common alleles,
ones that may have smaller effect sizes. Several of the known loci have candidate genes with
clear roles in B-cell biology or the apoptosis pathway. Although additional individual
variants may be discovered with larger studies, a more integrated approach is needed to
investigate the underlying biology of CLL susceptibility. This may include pathway studies
and integration of other data types (e.g., gene expression, epigenetics, or protein expression).
Identification of rare variants through next generation sequencing will also be another
research avenue; however, this will require very large studies or a circle back to pedigree
studies. Studies in populations other than those of European ancestry also provide an
opportunity to not only discover novel loci but also hone in on the loci that are shared across
populations, but perhaps varying in frequency of the susceptibility alleles. Similarly, as
larger studies are being conducted on closely related hematological malignancies (e.g., other
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non-Hodgkin lymphoma subtypes), shared SNPs, loci, or pathways may be identified that
potentially may shed light on shared familiarity of these conditions. Finally, none of the
aforementioned studies replace the need for in vitro or in vivo functional studies. The
GWAS discovered findings provide a logical first step for functional studies, which should
point us towards a more comprehensive understanding of the genetic contributions to CLL.
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Table 1
GWAS discovered loci and SNPs
Locus Nearest gene Published SNP Location Refs






2q33.1 CASP10, CASP8 rs3769825 201,819,625 43
2q37.1 SP140 rs13397985 230,799,467 33
2q37.3 FARP2 rs757978 242,019,774 36
4q25 LEF1 rs898518 109,236,273 43
6p25.3 IRF4 rs872071 356,064 33
6p21.32 HLA rs674313 32,686,060 39
6p21.31 BAK1 rs210142 33,654,815 41
8q24.21 MYC rs2456449 128,262,163 36
9p21.3 CDKN2B-AS1 rs1679013 22,196,987 43
10q23.31 ACTA2, FAS rs4406737 90,749,704 43
11p15.5 C11orf21, TSPAN32 rs7944004 2,267,728 43
11q24.1 SCN3B rs735665 122,866,607 33
15q15.1 BMF rs8024033 38,190,949 43
15q21.3 RFXDC2 rs7169431 54,128,188 36
15q23 RPLP1 rs7176508 67,806,044 33














19q13.3 PRKD2 rs11083846 51,899,494 33
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